China NMPA Drug Inspection - Bayer Healthcare Co., Ltd. - Moxifloxacin Hydrochloride Tablets
China NMPA drug inspection for Bayer Healthcare Co., Ltd. published June 05, 2020. Drug: Moxifloxacin Hydrochloride Tablets. The Beijing Municipal Drug Administration released its first-quarter 2020 report (Announcement No. 18) regarding drug qu
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Bayer Healthcare Co., Ltd. published June 05, 2020. Drug: Moxifloxacin Hydrochloride Tablets. The Beijing Municipal Drug Administration released its first-quarter 2020 report (Announcement No. 18) regarding drug qu
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Company
Bayer Healthcare Co., Ltd.Inspection Date
Unknown Date
Product Type
ID: 91ed5515-1992-40f4-9453-f4db5437fbb6
View on DashboardTransform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox